{{Rsnum
|rsid=506585
|Chromosome=2
|position=21174310
|Orientation=plus
|GMAF=0.1887
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 58.4 | 32.7 | 8.8
| HCB | 97.8 | 2.2 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 36.7 | 49.0 | 14.3
| ASW | 54.4 | 33.3 | 12.3
| CHB | 97.8 | 2.2 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 71.3 | 23.8 | 5.0
| LWK | 59.1 | 33.6 | 7.3
| MEX | 65.5 | 32.8 | 1.7
| MKK | 64.7 | 31.4 | 3.8
| TSI | 55.9 | 39.2 | 4.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs506585
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19802338
|Annotation=Phenotype: In a GWAS, this SNP was significantly associated with plasma concentrations of apolipoprotein B and LDL-C. Study size:6382. Study population/ethnicity: Caucasian women. Significance metric(s): ApoB:P = 7.7 x 10(-14) ;LDL-C: p = 9.3 x 10(-9). Type of association: CO; GN
|Drugs=
|Drug Classes=
|Diseases=Cardiovascular Diseases
|Curation Level=Curated
|PharmGKB Accession ID=PA165111807
}}

{{PMID|18262040|OA=1
}} LDL-cholesterol concentrations: a genome-wide association study.

{{PMID|19936222|OA=1
}} Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs506585
|overall_frequency_n=101
|overall_frequency_d=128
|overall_frequency=0.789062
|n_genomes=49
|n_genomes_annotated=0
|n_haplomes=83
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}